CORTEXA THERAPEUTICS
DEAD

Serial Number

99192698

Owner

Cortexa Therapeutics, Inc.

Attorney

Michael K. Kelly

First Use Date

Apr 20, 2025

Filing Date

May 19, 2025

Add to watchlist:

No watchlists yet
View on USPTO

CORTEXA THERAPEUTICS Trademark

Serial Number: 99192698

CORTEXA THERAPEUTICS is a trademark filed by Cortexa Therapeutics, Inc. on May 19, 2025. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Cortexa Therapeutics, Inc.

4435 E Chandler Blvd
Phoenix, AZ 85048

Entity Type: 03

Trademark Details

Filing Date

May 19, 2025

Registration Date

Not Registered

First Use Anywhere

April 20, 2025

First Use in Commerce

April 20, 2025

Goods & Services

Biotechnology research; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development in the field of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), Huntington’s Disease, and vascular dementia; Scientific research for medical purposes in the field of Central Nervous System (CNS) disorders; Scientific study and research in the field(s) of treatment and management of CNS disorders; Laboratory research services relating to pharmaceuticals; Clinical research in the field of Central Nervous System (CNS) disorders medical treatment; Testing of pharmaceuticals; Scientific research in the nature of conducting clinical trials for others in the field of Central Nervous System (CNS) disorders treatments; Research and development services in the field of pharmaceutical preparations; Laboratory services for biomanufacturing CRO-contracted compounds; Laboratory research in the field of chemical analyses for analog development and PK/PD profiling; Pharmaceutical research and development; Conducting early evaluations in the field of new pharmaceuticals; Research and development and consultation related thereto in the field of pharmaceutical therapeutic strategy and trial design advisory; Medical and scientific research in the field of Amyotrophic Lateral Sclerosis (ALS)

Providing medical information in the field of Amyotrophic Lateral Sclerosis (ALS); Pharmaceutical advice; Providing health information in the field of Central Nervous System (CNS) disorders; Medical analysis services relating to the treatment of persons; Providing information in the field of the diagnosis and treatment of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), Frontotemporal Dementia (FTD), Huntington’s Disease, and vascular dementia via a website; Consulting services in the field of the diagnosis and treatment of Amyotrophic Lateral Sclerosis (ALS); Consulting services to health care providers in the field of treating life-changing or life-threatening diseases; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of Central Nervous System (CNS) disorders; Medical screening services in the field of Central Nervous System (CNS) disorders

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 22, 2026 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 22, 2026 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Oct 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Oct 8, 2025 CNRT
ASSIGNED TO EXAMINER
Oct 1, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 25, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 25, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
May 19, 2025 MAFR
NEW APPLICATION ENTERED
May 19, 2025 NWAP